Abstract Tumor necrosis variable-associated apoptosis-inducing ligand (TRAIL) is often a cytotoxic cytokine that induces most cancers cell Dying by binding to TRAIL receptors. Thanks to its selective cytotoxicity toward cancer cells, Path therapeutics, including recombinant TRAIL and agonistic antibodies focusing on TRAIL receptors, have garnered consideration as promising most cancers https://ezetimibe69012.blogerus.com/39990465/666-15-an-overview